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There are more things in heaven and in earth, Horatio, 
Than are dreamt of in your philosophy... 
      W. Shakespeare, Hamlet act I scene 5 
1. Introduction 
The aim of this chapter is to overview the promises of the pioneering field of 
pharmacogenetics towards personalized medicine, completely changing the present 
therapeutic paradigm of “one dose fits all patients” and “trial-and-error” prescriptions to 
“matching the right dose to the right, specific genetic signature of the patient and at the 
right time”. The review points out the evolution from pharmacogenetics to 
pharmacogenomics, as well as the impact of genome-wide-associated studies (GWAS) and 
next generation sequencing technologies on deciphering “missing heritability” and on 
validation and approval of pharmacogenetic biomarkers as it is reflected both in regulatory 
authorities recommendations and from consortia perspectives. Pharmacogenetics’ 
translation from bench towards clinical practice in personalized medicine and drug 
discovery and development underlies the increasing benefits of pipeline pharmacogenetics, 
especially in the high-priority domains, as well as the emergence of the electronic health 
records-, biobanking- and bioinformatics-driven pharmacogenetics within extended 
international networks. More effective and successful integration of pharmacogenetics in 
clinical practice should address challenges regarding bioethics, insurance and privacy, 
consensus scientific guidelines, education, pharmacoeconomics and regulatory policy 
issues. Finally, there are illustrated the promising perspectives opened by: the interrogation 
of extensive electronic databases comprising clinical phenotype and genotype information; 
discovery of novel biomarkers by mining epigenoms, “junk DNA”, mitochondrial and RNA 
polymorphisms; and integration of nanotechnologies, in order to achieve the major objective 
of selecting the right therapeutic strategy endowed with the highest level of efficacy and 
safety among a predictable segment of the genotyped patients’ population. 
2. Pharmacogenetics: Conceptual evolution to pharmacogenomics 
2.1 Pharmacogenetics: Brief history and definition 
The first clinical observations of interpatient variability in clinical response to standard 
therapeutic doses and the pioneering contributions of Sir Archibald Garrod, Arno Motulsky, 
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Friedrich Vogel and Werner Kalow led to the concept of pharmacogenetics. In “Inborn Factors 
of Disease” (1909), Sir Archibald Garrod noticed the implication of the “biochemical 
individuality” in the interpatient variability of the metabolism and efficacy of the standard 
regimens. In 1950s there were described sensitivity to primaquin and the risk of hemolytic 
anemia of the patients with glucose-6-phosphate deficiency (G6PD), slow metabolizers/ 
acetylators of standard doses of isoniasid among tuberculosis patients with increased risk of 
peripheral neuropathy, prolonged apnea after succynilcholine administration, in relation to 
hereditary factors. The involvement of genetic factors in the adverse drug reactions was 
mentioned for the first time by Arno Motulsky – considered the father of the 
pharmacogenetics – in his paper “Drug Reactions, Enzymes and Biochemical Genetics” (1957). 
The concept of pharmacogenetics was introduced by Friedrich Vogel in “Moderne problem 
der humangenetik” (1959) as the study of genetic determinism of the interindividual 
variability to drugs action. The first monography on pharmacogenetics „Pharmacogenetics: 
Heredity and the Response to Drugs“ (1962) belongs to Werner Kalow, based on his 
pioneering work on the relation between genetic polymorphisms of butyrilcholinesterase and 
the risk of prolonged apnea to the standard therapeutic doses of succynilcholine. (Liewei et al., 
2011; Grossman & Goldstein, 2009; Tepper & Roubenoff, 2009) 
Pharmacogenetics correlates genetic factors to the interindividual variability in drug-
response phenotypes and has mainly focused on the association between monogenic 
polymorphisms and the variation of the drugs’ metabolism. (Liewei et al., 2011) 
Pharmacogenetics has the potential to increase the clinical benefit and reduce the risk of 
adverse drug reactions (ADR) in outliers, i.e. people whose drug responses are not 
“average”. (Woodcock & Lesko, 2009) 
Pharmacogenetic studies involve the identification of genetic classifiers or markers used to 
predict interpatient variability concerning drugs’ efficacy and/or safety. These genetic 
markers could be generated through one of the following approaches: candidate gene 
approach, pathway-based approach or whole genome scan (also cited as Genome Wide 
Association Studies GWAS) approach.  
2.2 Candidate gene, pathway-based and genome-wide studies  
In the candidate gene approach,  a panel of genes (candidate gene list) is generated based on 
the hypothesis in question to include drug target and mechanism pathway genes, as well as 
genes encoding the drug-metabolizing enzymes and membrane transporters involved in 
absorption, distribution, metabolism and elimination (i.e., drug pharmacokinetics). (Spraggs 
et al., 2009) The candidate gene approach has been applied by the majority of 
pharmacogenetics studies to detect associations between known single nucleotide 
polymorphisms (SNPs) and clinical or pharmacological end points, especially in the cases 
where there is a major drug metabolism or target gene that has a polymorphism that 
significantly changes its function. It is a hypothesis-driven approach that enables a study-
design adjustment so as to acquire sufficient statistical power. The major drawback resides 
in its inconsistency in validating genetic markers, especially in cases where allelic variants 
are not highly penetrant, making the results of these studies difficult to interpret. (Wu et al., 
2008 as cited in Sissung et al., 2010; Sissung et al., 2010) 
The pathway-based approach uses foreknowledge of both genetic variants and the 
pathways in which they are involved, therefore this approach has proven particularly useful 
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in identifying and characterizing pharmacogenetics end points within studies aimed to test 
the interaction between genes. The major obstacles reside in: the necessity of machine 
learning techniques; complexity of studies requiring larger sample sizes than candidate gene 
approaches; difficulty to validate gene–gene interactions due to incomplete understanding 
of the fundamental biology of the pathways’ interactions. (Sissung et al., 2010) 
The genome-wide approach is useful in determining the most significant SNPs associated 
with a phenotype amongst a high-density set of polymorphisms. GWAS are most useful to 
discover SNP associations where prior knowledge (i.e., mechanism, inheritance pattern, 
protein interactions and so on) is not available. Genome-wide association studies require a 
careful design of key issues like: a) type of study (case/control or continuous phenotype) 
according to the key-question and with a well-defined phenotype across all samples; b) 
sample sizes, dependent on specific effect size and type of study; c) population stratification 
between cases and controls; d) genotyping technology; e) raw data quality control and 
processing. (Wu et al., 2008 as cited in Sissung et al., 2010; Shianna, 2009)  
GWAS are discovery-driven rather than hypothesis-driven, they evaluate multiple 
hypotheses and require large sample size, cost and computing power, often resulting in 
weak statistical signals and false positives (i.e., Type I error). Frequently, GWAS require a 
two-stage design where discoveries are made using a high-density SNP array and are then 
validated using additional patient sets and a more hypothesis-driven approach. (Wu et al., 
2008 as cited in Sissung et al., 2010) Although recently GWAS application has dramatically 
increased, few studies have been published partially due to its primarily exploratory nature 
that requires further replication in large size and independent samples of the initial findings 
above the genome-wide significance and after correcting for multiple testing. For instance, 
in the case of antipsychotics drugs (ziprasidone, olanzapine, risperidone, iloperidone) 
GWAS revealed SNPs located in intergenic regions, but the functions of the variants on the 
drugs’ response are still unknown. (Jian-Ping Zhang, 2011) 
The application of GWAS in a population-based cohort allows the study of all possible 
genetic determinants of a drug response’s phenotype in a hypothesis-free (i.e., unbiased) 
approach and is performed on commercially available, efficient and cost-effective high-
throughput, genome-wide genotyping platforms (such as: Illumina’s Infinium BeadChips, 
Affymetrix GeneChips) targeting 100,000 SNPs, or 500,000 SNPs or even 1,000,000 SNPs of 
the genome. (Spraggs et al., 2009)   
Functional SNPs for each selected gene are added based on a literature survey and 
especially by using a minimum set of “tagging SNPs” (tSNPs) sufficient to capture the 
common genetic variations (whose minor allele frequency is higher than 2-5%) which allow 
almost complete genome coverage for the most of genetic diversity in human populations. 
(Grossman & Goldstein, 2009) Tagging SNPs greatly increase the genomic coverage of 
genetic variability and they reflect the well-established patterns of linkage disequilibrium, 
making possible to genotype only the tagging SNPs in order to capture the content of other 
associated SNPs in the region. The HapMap database with its incorporated software was 
created by The International HapMap Project (2005) and is an appropriate publicly available 
resource for selecting globally useful “tagging SNPs” that has been implemented by both 
commercial companies and academic laboratories. Tagging SNPs are chosen mainly based 
on r2 threshold, besides a variety of other criteria (ethnicity, SNP’s functional effects etc.). 
The r2 threshold is the correlation coefficient between any observed marker and a putative 
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causal allele and is a study-independent measure of SNP utility, being considered a leading 
standard for evaluating performance of marker sets; the minimum customary pair-wise 
value for r2 is 0.7-0.8. (Bakker, 2005 and Pe’er, 2006 as cited in Grossman & Goldstein, 2009) 
There are currently commercially available arrays (SNP chips) that contain close to 1 million 
tagging SNPs with excellent genomic coverage for most populations as defined in HapMap 
Project. For example, Illumina HumanMap 300 has essentially the same statistical genomic 
coverage as the Affymetrix Mapping 500 K Set, while the Illumina HumanMap 550 array is 
statistically superior for GWAS. (Hirschhorn & Daly, 2005; Barrett & Cardon, 2006; Pe’er et 
al., 2006, as cited in Shianna, 2009) 
2.3 Pharmacogenomics’ scope and goals 
The elucidation of the sequence of the human genome in 2001 and the identification and 
analysis of functional elements in the human genome by the ENCODE (ENCyclopedia Of 
DNA Elements) Project represented major steps towards a more comprehensive 
characterization of all functional elements in the human genome. Moreover, the HapMap 
Project aims to generate a haplotype map of the human genome, describing the common 
patterns of the human genetic variation which would affect complex, multigenic diseases and 
responses to drugs and environmental factors. The emergence of the term pharmacogenomics 
was possible after the availability of the human haplotype map (HapMap) and of high-
throughput genotyping platforms that have been facilitating more systematic genetic screens 
for new and clinically important drug targets. (Passetti et al., 2009) Therefore the concept of 
pharmacogenomics has progressively evolved from pharmacogenetics and expands beyond 
monogenic pharmacokinetics traits, making also the transition from associative genetic studies 
based on candidate gene hypothesis towards genome-wide association/screening studies 
(GWAS) in order to identify genetic biomarkers with prognostic role for disease progression 
and predictive capacity for drug responsiveness.  
The evolution from pharmacogenetics to pharmacogenomics was due to: a) the integration 
of –omics technologies and bioinformatics into the genomic medicine and systems 
pharmacology; b) the acquisition of catalogued genomic and clinical data bases (such as 
“Pharmacogenetics and Pharmacogenomics Knowledge Base”, „Connectivity Map”, 
International HapMap Project); c) identification of SNPs that ‘tag’ much of the common 
haplotype variation across any genomic region of a given population; d) positive genetic 
associations studies between specific genetic signature of patients and variations to standard 
therapeutic regimens; e) analytical and clinical validation of genetic biomarkers predictive 
for drug response. (Ayslin et al., 2009) 
According to the US Food and Drug Administration (FDA)-approved definitions, 
pharmacogenetics is ‘the study of variations in DNA sequence as related to drug response’ 
(Liewei et al., 2011), and currently is regarded as a subdomain of the much more 
comprehensive pharmacogenomics that is FDA-defined as ‘the study of variations of DNA 
and RNA characteristics as related to drug response’. (Trent, 2010) 
Pharmacogenomics studies the differential expression profiles at the level of the entire human 
genome in complex interaction to drugs, in a systemic and integrative manner. The 
identification of all the genetic and epigenetic differences that are the cause of phenotypic 
variations in patients’ responsivity to therapy is a major objective in pharmacogenomics. 
(Passetti et al., 2009) Each person’s phenotype is best determined by the paired combination of 
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the genome and the epigenome. Epigenetics and epigenomics refer to the study of factors that 
affect gene (or, more globally, genome) function, but without an accompanying change in 
genes. Typical epigenetic factors might be illustrated by changes in DNA methylation or in 
chromatin that modify genome structure and hence influence gene expression even in the 
absence of variations of DNA sequence. (Willard, 2009) Therefore, to achieve the main goal of 
therapy individualization, pharmacogenomics should also evaluate genetic variation in the 
context of the individual: gene–gene, gene–drug and gene–environment interactions which 
might influence the course of a disease and the response to treatment. (Passetti et al., 2009)  
Pharmacogenomics is the interface between genomic medicine and systems pharmacology, 
the two essential pillars supporting the gateway to personalized medicine. (Aislyn et al., 
2009) The transdisciplinary field of genomic medicine refers to the use of large-scale 
genomic information and to the consideration of the full extent of an individual’s genome, 
proteome, transcriptome, metabolome and/or epigenome in the practice of medicine and 
medical decision-making. Genomic medicine’s approaches include gene expression 
profiling to characterize diseases and define diseases’ prognosis, genotyping variants in 
genes involved in drug metabolism or action in order to select the correct therapeutic 
dosage for an individual, scanning the entire genome for millions of variants that influence 
an individual’s susceptibility to disease, or analyzing multiple biomarkers to monitor 
therapy and to provide predictive information in presymptomatic individuals. (Willard, 
2009) Genomic medicine brings together knowledge on the relationships between genetics, 
pathophysiology and pharmacology, thus forming the base for systems pharmacology. 
Experimental and computational approaches enable systems pharmacology to provide 
holistic, mechanistic information on disease networks and drug responses, and to identify 
new drug targets and specific drug combinations. Network analyses of interactions involved 
in pathophysiology and drug response across multiple scales of organization, from 
molecular to whole organism, will allow the integration of the systems-level understanding 
of drug action with genomic medicine, thus generating the personalized medicine. (Aislyn 
et al., 2009) Personalized medicine refers to a rapidly advancing field of health care that 
takes into account each person’s unique clinical, genomic and environmental information. 
The goals of personalized medicine are to optimize preventive health care strategies and 
outcomes of drug therapies for each individual, while people are still healthy or at the 
earliest stages of disease, by an unprecedented customization or tailoring of medication 
types and dosages and/or prophylactic measures. (Willard, 2009) 
The great promise of pharmacogenomics towards personalized medicine resides mainly in 
generating an individualized therapeutic guide, highly predictive for much safer and more 
efficient drug and doses choice for an accurately predicted, homogenously genotype-
segment of patients who are responders to the treatment, rather being focused around each 
individual specifically. (Grossman & Goldstein, 2009) 
Pharmacogenomics aims to individualize therapy on the patient’s specific genetic profile, by 
matching the right drug to the right patient at the right time. Pharmacogenomics’ translation 
from bench into clinical practice is broadening the perspective of personalized medicine so 
as in the near future we might rely on a “DNA chip”/“pharmacogenomic card” specific to 
each patient and on each genotype preemptively recorded in electronic medical records in 
order to individualize both the diagnostic procedures and the safest and most efficient 
medications prior to treatment initiation. 
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3. Pharmacokinetic pharmacogenetics 
Relevant allelic variants to drug treatment’s outcome have been discovered in the genes 
encoding enzymes and transporters involved in drug pharmacokinetics: absorption, 
distribution, metabolism and excretion (ADME). Enzymes involved in the 
biotransformation of xenobiotics are classified as phase I or phase II. Phase I enzymes 
catalyze hydrolysis, reduction and oxidation reactions, while phase II enzymes catalyze 
conjugation reactions such as sulfation, acetylation and glucuronidation. (Sissung et al. 
2010). The majority of phase I reactions are catalyzed by the cytochrome P450 (CYP) 
enzymes. There are 57 cytochrome P450 (CYP) genes and about the same number of 
pseudogenes, which are grouped according to their sequence similarity into 18 families 
and 44 subfamilies. However, only three of those families, CYP1, CYP2 and CYP3, 
catalyze most phase I reactions of drugs; over 75% of prescribed drugs are metabolized at 
least in part by three subfamilies: CYP3A, CYP2D6 and CYP2C. (Zanger et al., 2008; van 
Schaik, 2008, as cited in Sissung et al., 2010) Phase II reactions significantly enable the 
excretion of drugs by considerably increasing the hydrophilicity of the substrate or 
deactivate highly reactive species. Key phase II enzymes include N-acetyltransferases 1 
and 2 (NAT1 and NAT2), thiopurine S-methyltransferase (TPMT), and the uridine 
diphosphate glucuronosyltransferase (UGT) family; polymorphisms in these genes have 
been shown to have clinical implications for a variety of diseases. (Zhou et al., 2008, as 
cited in Sissung et al., 2010) 
3.1 Pharmacogenetics of drug-metabolizing enzymes 
Biotransformation of the 200 most often prescribed drugs is catalyzed by members of the 
CYP3A family (37% of the drugs), followed by CYP2C9 (17%), CYP2D6 (15%), CYP2C19 
(10%), CYP1A2 (9%), and CYP2C8 (6%), while CYP2B6 and other CYP isoforms (CYP2A6 
and CYP2E1) participate in the metabolism of 4% and 2% of the drugs, respectively. The 
clinically well-established polymorphisms of CYP2C9, CYP2C19, and CYP2D6 genes are 
involved in approximately half of these top 200 drugs, since many of the drugs used in high-
prevalence diseases in the Western countries are known to be metabolized by these CYPs. 
(Zanger et al., 2008) 
CYP2C9, highly expressed in liver, metabolizes many weakly acidic substances like the 
anticoagulant warfarin, the anticonvulsants phenytoin and valproic acid, cardiovascular 
drugs like rosuvastatin and losartan, and several nonsteroidal anti-inflammatory drugs 
(NSAIDs). Many of these drugs have a narrow therapeutic index, and variations in CYP2C9 
activity are among the recognized factors for adverse drug reactions. In vitro and clinical 
studies have consistently demonstrated that the CYP2C9*2 and *3 alleles are associated with 
significant, but highly variable, reductions in intrinsic clearance depending on the particular 
substrate; for instance, CYP2C9*3 allele might be associated to up to 90% reduction in the 
enzymatic activity of the CYP2C9 protein. The prevalence of CYP2C9*2 and *3 alleles is 35% 
in Caucasians and much lower in black and Asian populations. Carriers of CYP2C9*2 and 
CYP2C9*3 alleles are poor metabolizers and have high plasma levels due to low clearance of 
the substrate-drugs, therefore they experience higher incidences of adverse drug reactions 
like hypoglycemia from antidiabetic drugs, gastrointestinal bleeding from NSAIDs, and 
serious bleeding from warfarin treatment. (Pilotto et al., 2007, and Flockhart et al., 2008, as 
cited in Zanger et al., 2008) 
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The CYP2C19 isozyme metabolizes preferentially proton-pump inhibitors (PPI) like 
omeprazole and pantoprazole indicated in gastroesophageal reflux disease, gastric and 
duodenal ulcer. The poor metabolizer (PM) phenotype results from two null alleles, leading 
to the absence of functional CYP2C19 protein, whereas extensive metabolizers carry at least 
one functional allele. The prevalence of null alleles is about 3–5% to white and black 
populations, whereas up to 20% of Asians are carriers of two null alleles. The two most 
common null alleles are CYP2C19*2 occurring exclusively in Caucasians, and CYP2C19*3 
occurring primarily in Asians. The PPI-efficacy depends on the plasma concentrations 
achieved over time, which are strongly influenced by CYP2C19 gene polymorphisms. PM 
subjects who are carriers of null alleles benefit from their lower metabolism rate because 
their drug levels are maintained higher for longer periods. On the contrary, subjects with the 
CYP2C9 *1/*1 wild-type genotype should receive higher doses of these PPIs in order to 
achieve stronger acid suppression compared to *1/*2 and *2/*2 subjects. (Kawamura et al., 
2007, as cited in Zanger et al., 2008; Zanger et al., 2008; Tomalik-Scharte et al., 2008) 
The clinical consequences of pharmacokinetic variability associated to genetic 
polymorphisms of CYP2D6 gene for tricyclic and selective serotonin re-uptake inhibitors 
antidepressants, beta-blockers, anticancer agent tamoxifen, as well as to the CYP2C9 genetic 
variants for AT1 (angiotensin II type 1) receptor antagonists (sartans), and anticoagulants 
(warfarin, acenocoumarol, phenprocoumon), are covered in other chapters of the book. 
The CYP3A4 subfamily contributes to the metabolism of the most diverse group of 
substrates of all human P450s, as their active sites are flexible enough to bind and 
metabolize many preferentially lipophilic, structurally large compounds, such as: the 
immunosuppressants cyclosporin A and tacrolimus, macrolide antibiotics like 
erythromycin, anticancer drugs like taxol, benzodiazepines, hydroxymethylglutaryl-
coenzyme A (HMG-CoA) reductase inhibitors like simvastatin and atorvastatin, and 
anesthetics. In addition, CYP3A4 is the only human drug-metabolizing P450 that shows a 
significant sex difference, in that women express approximately 1.5- to 2-fold more CYP3A4 
and have higher in vivo clearance of several typical CYP3A4 drug substrates than men. 
Although a number of large-scale sequencing and phenotype–genotype correlation studies 
have been carried out, the functional effects of CYP3A4 gene polymorphisms on drugs 
pharmacokinetic variability remain controversial. (Zanger et al., 2008) However, CYP3A4 
basal and inducible expression phenotype might be influenced by other genes, such as: a) 
multiple drug resistance gene MDR1 whose 2677T (Ser893) allele induced higher basal 
CYP3A4 expression and activity, whereas the 2677G allele showed a higher rifampicin 
induction ratio in primary hepatocytes; b) pregnan X receptor PXR gene polymorphisms 
mostly located in promoter or intron 1 regions associated with CYP3A4 basal and inducible 
expression levels. (Liu, 2007 and Lamba, 2008, as cited in Zanger et al., 2008) 
N-acetyltransferase type 2 (NAT2) is a phase II drug metabolizing enzyme responsible for 
hepatic bioconversion of major antituberculosis agent isoniazid to acetylisoniazid. Isoniazid 
is a pivotal agent in the treatment of tuberculosis, that remains a global emergency due to 
the growing prevalence of drug-resistant Mycobacterium tuberculosis and of HIV infection. 
NAT2 gene is affected by a bimodal distribution polymorphism (acetylation polymorphism) 
described after clinical observation of more frequently and more severely peripheral 
neuropathy and hepatotoxicity as adverse drug reactions to the slow-acetylators patients. 
These patients have mean elimination half-lives of 180 min. in comparison with 80 min. for 
rapid-acetylators. Carriers of at least one wild-type allele (NAT2*4) or a high-activity variant 
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allele (NAT2*12) have proven high NAT2 enzymatic activity (rapid acetylators), whereas 
those with two low-activity variants are slow acetylators. Rapid acetylators are more 
prevalent in East Asia (58-90%) than in Europe (32-43%). Tailoring isoniazid therapy means 
to increase isoniazid dose to rapid acetylators so as to achieve therapeutic efficacy and to 
reduce the dose administered to slow-acetylators so as to avoid adverse drug reactions 
while maintaining the desired antituberculosis effect. (Tomalik-Scharte et al., 2008) 
Pharmacogenetics of other phase II drug-metabolizing enzymes is discussed in detail in 
other chapters for: thiopurine-S-methyl-transferase (TPMT) polymorphisms and the 
necessity to individualize the therapeutic doses of mercaptopurine and azathioprine; 
dihydropyrimidine dehydrogenase deficiency syndrome noticed during the treatment with 
standard doses of fluoropyrimidines (5-fluorouracil) to a segment of cancer patients carriers 
of certain genetic mutations; the pharmacokinetic variability and increased risk of 
myelotoxicity noticed for the anticancer drug irinotecan as a consequence of genetic 
polymorphism of UDP-glucuronosyltransferase (UGT1A1). 
3.2 Pharmacogenetics of transporters 
Transporters play a critical role in ADME because they are involved in the efflux and/or 
influx of drugs via active transport or facilitated diffusion, thus transporters affect drug 
uptake, bioavailability, targeting, efficacy, toxicity and clearance and they should be 
considered in combination with metabolic enzymes when discussing drugs’ outcomes. Two 
types of transport superfamilies, ATP-binding cassette (ABC) proteins generally acting as 
efflux pumps and solute-linked carrier (SLC) proteins as typically influx transporters, are 
responsible for the majority of drug and endogenous substrates transport. Many 
transporters have a broad range of substrates; for instance, ABCB1, also known as P-
glycoprotein and MRD1, transports several classes of drugs, including anticancer agents, 
antibiotics, immunosuppressants and statins. (Sissung et al., 2010) 
Largely as a result of the Human Genome Project, great advances in molecular biology, 
sequencing methods and availability of genome-wide technologies, genetic variants across the 
entire genome, including coding and noncoding regions of multiple transporter genes were 
identified, functionally characterized and associated with various drug-response phenotypes. 
Thus, functionally relevant polymorphisms were discovered for the members of ABC and SLC 
superfamilies of transporters and have been widely studied with positive associations to 
individual susceptibility to drug-induced adverse events, to variations in drug plasma levels, 
or renal clearance. (Yee SW et al., 2010) For instance, the organic anion transporting 
polypeptide polymorphism SLCO1B1*5 (Val174Ala, c.521T>C) is associated with variability in 
response to statins (atorvastatin, pravastatin, pitavastatin, rosuvastatin, simvastatin), 
repaglinide, fexofenadine and methotrexate. The SLCO1B1 genotype affects the transport 
function and may predict, in a substrate-dependent manner, the attenuated lipid-lowering 
response to statin therapy. Moreover, stronger evidence has been provided for the role of the 
SLCO1B1 genotype in predicting the development of myopathy among patients receiving 
simvastatin in 40 mg doses. (Yee SW et al., 2010; Romaine et al., 2010) Prescribing relatively 
low dose of simvastatin to those who are heterozygous for the high risk allele SLCO1B1 could 
reduce the incidence of myopathy by nearly 60%, while avoiding simvastatin only to those 
who are homozygous for the risk allele (nearly 2% of the population analyzed by the SEARCH 
group) could reduce the incidence of myopathy by 25%. Further investigation is required to 
identify the optimal therapeutic approach. (Nakamura, 2008)  
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Furthermore, organic cationic transporter OCT1 (R61C, P160L, G401S, 420del and G465R) 
and OCT2 (A270S) polymorphisms are associated with response’s variability to metformin, 
cisplatin and imatinib. The ABCG2 genotype (rs2231142, Gln141Lys, c.421C>A) is associated 
with variable pharmacokinetics parameters of atorvastatin, rosuvastatin, gefitinib, 
sulfasalazine and diflomotecan. ABCB1 gene polymorphisms (c.3435C>T, 2677G/T/A) 
and/or ABCC2 (-24C>T, c.1249G>T, c.3972C>T, c.4544C>T) are related to therapeutic and 
adverse effects to anticancer, antiviral and/or antiepileptic drugs. (Yee SW et al., 2010)  
SNPs of ABCB1 were found to be associated with moderate-to-severe neutropenia, hand–
foot syndrome and diarrhoea in colorectal patients treated with capecitabine or 5-
fluorouracil. (Gonzales-Haba et al., 2010) 
Nonsynonymous (coding) SNPs generally appear to affect the expression level of the 
transporter on the plasma membrane and the transporter function in a substrate-dependent 
manner. In comparison to nonsynonymous variants, noncoding region variants (such as in 
the proximal promoter region) are more abundant, minor allele frequencies being often 
higher and the functional consequences are more modest and highly dependent upon the 
haplotype. The frequency of noncoding polymorphisms are greater in ABC transporters 
highly expressed in the liver than in SLC predominantly expressed in the kidney. The 
projected functional map of the ‘transporter genome’ will characterize gene regions 
(enhancer regions upstream, downstream and intronic regions of transporter genes) having 
relevant functional variants and it will be superimposed on the genetic variants resulted 
from the 1000 Genomes Project in multiple ethnic populations. (Yee SW et al., 2010) 
3.3 AmpliChip™ CYP450 test 
In 2005, the FDA approved the first pharmacogenetic test AmpliChip™ CYP450 Test (Roche 
Molecular Systems, Inc., NJ, USA) based on Affymetrix (CA, USA) microarray technology 
for genotyping 27 alleles in CYP2D6 and three alleles in CYP2C19 genes associated with 
different metabolizing phenotypes. The test is recommended for the assessment of the 
patient’s metabolizing status for each drug that is a substrate for CYP450 isoenzymes 2D6 
and 2C19 and for the dose adjustements in outlier patients who are either ultrarapid- (UM) 
or poor-metabolizers (PM), in order to achieve the therapeutic efficacy and to avoid the risk 
of severe adverse reactions. (Squassina et al., 2010) Key genetic mutations associated with 
clinical relevance on drug plasma concentrations and risk of either lack of efficacy for UM or 
adverse drug reactions for PM, are used to predict the metabolizer phenotype (ultrarapid, 
extensive, intermediate and poor metabolizers). FDA has included these biomarkers only as 
informational pharmacogenetic tests on labels of drugs mainly metabolized by these 
pathways, such as: CYP2C19 genotyping for prasugrel, voriconazol, (es)omeprazole, and 
genotyping CYP2D6 for tamoxifen, atomoxetine, fluoxetine, paroxetine, amitriptyline, 
aripiprazole, risperidone, codeine, tramadol, timolol, propranolol, carvedilol. The purpose 
of these informational pharmacogenetic tests is to improve drug safety by dose optimization 
based on genotypes predictive for poor- or ultrarapid-metabolizer status, as well as to avoid 
high plasma concentration when co-administered with other drugs which are CYP2D6 
strong inhibitors. (Squassina et al., 2010) 
For instance, patients with poor metabolizer phenotype associated to null alleles CYP2D6*4, 
*3, *5, or CYP2D6*6, will have higher risk of the adverse reaction tardive diskinesia at 
standard doses of antipsychotics. The individualized doses for these PM patients will be 
reduced than standard regimens designed for wild-type normally functional allele. On the 
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contrary, to achieve the required level of therapeutic efficacy, ultrarapid metabolizers who 
are carriers of CYP2D6*Nxn multiple functional alleles will be treated with higher doses 
than those standard recommended for the “average” patients population able to normally 
metabolize the drugs. However, mothers with phenotype of ultrarapid metabolizers will 
rapidly convert standard doses of codeine into morphine thus increasing the risk of CNS 
depression of their breast-fed babies; in such cases of prodrug bioconversion, dose 
optimization requires to be lower than the standard dose. (Loo et al., 2010) 
Although it is widely available in commercial labs, the AmpliChip™ CYP450 Test has still a 
limited clinical value because it is expensive (over $600/test), time-consuming (i.e. about 
two weeks), and yet there are no prospective study to demonstrate the cost-effective benefit 
of genotyping patients and selecting and dosing antipsychotic drugs accordingly. (Jian-Ping 
Zhang, 2011)  
3.4 DMET Plus Panel genotyping platform 
While the field of pharmacogenetics is moving towards exploratory, large-scale analyses of 
the interaction between genetic variation and drug treatment, the Drug Metabolizing 
Enzymes and Transporters DMET Plus Panel (Affymetrix) genotyping platform has proven 
a significant research tool. The DMET Plus Panel platform is a low- to mid-scale pathway-
based, hypothesis-driven and exploratory pharmacogenetic approach, which interrogates 
1936 genetic variations (copy-number variations, insertions/deletions, biallelic and triallelic 
single nucleotide polymorphisms SNPs) in 225 genes involved in the absorption, 
distribution, metabolism and elimination (ADME) of a very wide range of therapeutics, as 
well as a number of genes which regulate intracellular processes that facilitate ADME 
through indirect relationships, thus comprising biomarkers for all FDA-validated genes and 
included in the drugs’ label. (Sissung et al., 2010; Squassina et al., 2010) 
The DMET Plus Panel platform is particularly useful for standardization of exploratory 
pharmacogenetics and for improvement of the clinical trials’ design conducted on smaller 
patient populations, having more variable end points and polygenetic traits, enabling 
increased statistical power and reduction of type I error (i.e., false positive) of GWAS. In 
addition, the application of DMET Plus Panel platform in phase I early clinical trials could 
identify the polymorphisms consistently associated with drugs’ pharmacokinetic 
variations, determine the recommended dose for later phase II and phase III trials based 
on genetic profile, thus reducing the attrition rate for new investigational agents. 
Moreover, besides detection of more common genetic variants, DMET is able to 
interrogate core biomarkers with an average minor allele frequency below 9%, in 
comparison with other SNP detection methods for minor alleles with an average 
frequency of 20%. However, the DMET Plus Panel platform’s utility resides mainly in the 
research setting, since it is not yet FDA approved, not customizable, does not include 
polymorphisms in many drug targets or in genes that are related to environmental 
exposures that could influence drug metabolism, and requires prospective clinical 
validation in order to translate the results in pertinent personalized medicine. (Sissung et 
al., 2010; Squassina et al., 2010) 
Although genetic variation in ADME genes is essential in personalizing therapy, 
polymorphisms in genes not directly responsible for drug metabolism or transport, but 
regulating expression of many genes that encode transporters and phase I and phase II 
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enzymes, play critical roles in patients’ response to treatment. For example, many SNPs in 
the nuclear receptors pregnane X receptor (PXR) and constitutive/active androstane 
receptor genes alter the expression levels of ABCB1, ABCC2, CYP2C8, CYP3A4, UGTs and 
sulfotransferases (SULTs) genes and contribute to variability in drug efficacy and safety. 
(Sissung et al., 2010) 
4. Pharmacodynamic pharmacogenetics 
Pharmacodynamics can be defined as the study of the biochemical and physiological 
effects of drugs and their mechanism of action. The effects of drugs result from their 
interaction with macromolecular components of the organism – receptors, which are 
grouped in a wide range of structural and functional families. The receptor occupancy by 
a particular drug class triggers biochemical cascades in target cells and modulates diverse 
intrinsic signaling pathways and functions, explaining the pharmacodynamic effect. (Ross 
& Kenakin, 2006) 
In addition to  genetic polymorphisms of ADME genes, the clinical outcome of standard 
therapeutic drug regimens is influenced by genetic variations in genes encoding drug 
targets (receptors, enzymes, ion channels, neurotransmitter’s transporter) and pathways 
affected by drugs. 
Since pharmacogenetics of heart diseases therapy, anticoagulants, asthma medication, 
anticancer agents including thiopurines, antidepressants, osteoporosis and antimalaria 
drugs, represent other distinct chapters of the book, in order to avoid overlapping 
information, this chapter will illustrate some functionally relevant polymorphisms of the 
drug target genes and their role in the interindividual variability of drugs’ 
pharmacodynamics, in a complementary manner to the aforementioned issues. 
4.1 Pharmacogenetics of drug hypersensitivity: Human Leukocytes Antigens (HLA) 
system 
In the field of highly active antiretroviral therapy (HAART), abacavir has created a 
translational roadmap for a pharmacogenetic biomarker from discovery to a test used in real 
clinical practice. The strong association between abacavir hypersensitivity reaction and 
HLA-B*5701 genotype has been demonstrated in both observational and blinded 
randomized clinical trials in racially diverse populations and represents the best example of 
the clinical utility of pharmacogenetic screening in HIV medicine. (Mallal et al., 2008) 
Hypersensitivity reaction to abacavir was observed during the clinical development 
program in approximately 5–8% of patients. Hypersensitivity reaction (HSR) symptoms 
appear early and resolve upon discontinuation of the drug, but worsen (and can be life-
threatening) with continued drug administration. Development of an abacavir skin patch 
assay enabled refinement of the hypersensitivity reaction phenotype. The biomarker HLA-
B*5701, validated in retrospective and prospective studies, was recommended in the drug 
label in the EU and USA. The prospective screening for this biomarker in Caucasians as high 
risk population allows a reduction in HSR frequency from 7.8% to 3.4%. (Trent, 2010)  
The increased benefit–to–risk ratio and the economic consequences of HLA-B*5701  
pre-screening of HIV-infected patients before abacavir treatment’s initiation were 
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demonstrated in a prospective double-blinded clinical trial sponsored by GSK. (Mallal et al., 
2008; Roses, 2009; Phillips et al., 2011) 
Moreover, consistent data support the association of the HLA class II allele HLA-DRB*0101 
with an increased risk of nevirapine-induced hepatotoxicity, as well as genotype-related 
peripheral neuropathy, hyperlipidaemia, lipodystrophy to HAART, nucleoside reverse 
transcriptase inhibitors-related pancreatitis and tenofovir-associated renal proximal 
tubulopathy. (Tozzi, 2010) 
Other recent examples of important HLA associations with drug hypersensitivity include 
HLA-B*1502 and Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) 
that are associated with carbamazepine in Han Chinese; HLA-B*5801 and SJS/TEN and 
drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic 
symptoms associated with allopurinol; HLA-B*5701 and flucloxacillin-induced liver 
injury. These pharmacogenetic associations hold the promise to convert the severe and 
adverse drug reactions into predictable and preventable ones in the future. (Phillips et al., 
2011) 
4.2 Pharmacodynamic pharmacogenetics of antipsychotics  
Pharmacogenetic investigations of schizophrenia susceptibility loci and genes controlling 
drug target receptors, the blood–brain barrier systems, and epigenetic mechanisms could 
lead to a molecular classification of treatment response and adverse events of psychotropic 
drugs. It is estimated that more than 70% of patients with chronic schizophrenia 
discontinued their antipsychotic drugs, owing to poor effectiveness or tolerability. Most of 
the pharmacodynamic pharmacogenetic studies in schizophrenia have evaluated treatment 
response using the candidate gene approach.  
The most relevant associations of genetics variants and antipsychotic clinical response 
were found for −141C Ins/Del in dopamine receptor gene DRD2, A-1438G in 5-
hydroxytriptamine/ serotonin receptor gene HTR2A, His452Tyr in HTR2A gene, Taq1A in 
DRD2, Ser9Gly in DRD3, T102C SNP in HTR2A, C759T SNP in HTR2C gene. For instance, 
patients who carry one or two Del alleles tend to have less favorable antipsychotic drug 
responses than patients with the Ins/Ins genotype in DRD2 −141C Ins/Del SNPs. Patients 
with G/G genotype for the HTR2A A-1438G polymorphism were less likely to respond to 
clozapine, olanzapine and aripiprazole, especially in negative symptoms, than other 
polymorphisms at this HTR2A locus. For the His452Tyr HTR2A genetic variants, the 
Tyr/Tyr genotype predicted poor response to clozapine. Higher risk of the adverse 
reaction tardive diskinesia was found for carriers of either: A2/A2 genotype at DRD2 
Taq1A locus, Gly allele at DRD3  Ser9Gly, or C allele for 5HT2A T102C. (Jian-Ping Zhang, 
2011) 
Furthermore, single-nucleotide substitutions in the promoter region of serotonin receptor 
type 2C (5-HT2C) could be associated with antipsychotics-induced weight gain and 
metabolic abnormalities in Han Chinese patients treated over a 10-week period. The C/C 
genotype from 5HT2C SNP C759T was associated with higher weight gain to clozapine and 
olanzapine. Comparable results were found in Caucasians treated 9 months with these anti-
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psychotics: carriers of the -795T variation gained less weight than study participants without 
this allele. (Broich & Moeller, 2008) 
A repeat length polymorphism of the gene encoding the serotonin transporter, 5-HTTLPR, 
involves insertion/deletion of a 44-bp segment located upstream of the transcription start 
site in the promoter region; patients carrying the long allele are about twice as likely to 
respond to treatment at 4 weeks and reach remission, and less likely to suffer from side 
effects, than patients with the short/short genotype; short allele is associated with poor 
response to clozapine and risperidone treatment. (Jian-Ping Zhang, 2011) Moreover, 
insertion/deletion polymorphism in the promoter region of the serotonin transporter gene 
is also associated to clinical phenotype response to the antidepressants citalopram, 
paroxetine and fluoxetine. (Yee SW et al., 2010) 
4.3 Pharmacodynamic pharmacogenetics of antidiabetics 
Thiazolidinedione drugs (pioglitazone, rosiglitazone) promote the binding of the 
transcription factor peroxisome proliferator-activated receptor-(PPAR-) to its DNA 
response element. Thiazolidinediones promote adipocyte differentiation, increase insulin-
stimulated glucose uptake into muscle, insulin suppression of hepatic glucose output, and 
insulin-stimulated lipolysis. The genetic variation Pro12Ala at the PPARG gene (encoding 
PPAR-) influences the clinical outcome: those carrying the Ala allele have a greater 
response to rosiglitazone, as well as a lower risk of edema after farglitazar or ragaglitazar 
therapy, than Pro/Pro homozygotes. (Kang ES et al., 2005 and Hansen et al., 2006, both cited 
in Pearson, 2009) The hypoglycemic effect of rosiglitazone might also be influenced by 
adiponectin gene ADIPOQ polymorphisms SNP +45T/G and SNP +276G/T: homozygotes 
G/G at +45 or +276 have a smaller clinical benefit. (Kang ES et al., 2005 as cited in Pearson, 
2009) Sulfonylureas (tolbutamide, glimepiride, glibenclamide) bind to the SUR1 moiety of 
the pancreatic β-cell KATP channel causing the channel to close and triggering insulin 
secretion. The clinical efficacy of sulfonylureas seems to be associated to genetic variations 
in the KCNJ11 gene (encoding the Kir6.2 subunit of the KATP channel) and the ABCC8 gene. 
(Pearson, 2009) The polymorphisms ABCC8 Ser1369Ala and KCNJ11 rs5210 and E23K are in 
strong linkage disequilibrium and significantly associated with variations in fasting plasma 
glucose levels induced by sulfonylureas. (Feng Y et al., 2008, Glyon AL et al., 2003 and Sesti 
G et al., 2006, all cited in Pearson, 2009)  
4.4 Pharmacogenetics of hepatitis C virus therapy 
Response to pegylated interferon-alfa (PEG-IFN) and ribavirin (RBV) therapy in chronic 
infection with hepatitis C virus (HCV) is variable and a sustained virological response (SVR) 
is dependent on genetic factors, hepatitis C viral load, patient age, sex, weight, liver fibrosis 
stage, and adherence to therapy. Strong predictive, clinically relevant effect of IL28B 
genotype on SVR shows that C/C genotype at rs12979860 has a greater HCV-genotype 1 
RNA decline from days 0-28 than patients with the C/T or T/T genotype. The IL28B genotype 
may also be considered in conjunction with virological response after 4 weeks: thus, patients 
with poor viral kinetics and T/T genotype at rs12979860 may decide to stop therapy. In 
North America, a commercial test for IL28B genotyping is now available and costs 
approximately $300. (Afdhal et al., 2011) 
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5. Pharmacogenetics’ translation from bench towards clinical practice in 
personalized medicine and drug design 
The great majority of drugs prescribed upon the classical paradigm of “one-drug-fits-all” and 
“trial-and-error” are effective only in 25-60% of the treated patients. Moreover, 50% from new 
chemical entities fail in the highly expensive phase III of clinical development. (Spraggs, 2009) 
Regulatory authorities FDA, European Medicines Agency (EMA) and the Japanese 
Pharmaceuticals and Medical Devices Agency (PMDA) recognize pharmacogenetics as an 
essential opportunity to predict drug responsiveness and to personalize therapy, and are 
increasingly integrating pharmacogenetic information to label updates of approved drugs, as 
well as incorporating pharmacogenetics into their regulatory review of new medicines. In 
addition, the regulatory framework that facilitates pharmacogenetics integration into drug 
development such as the Voluntary Exploratory Data Submissions in the USA and the 
Pharmacogenomics Briefing Meetings in Europe and Japan, as well as the more recent, formal 
biomarker qualification by the regulators are developed. (Surh et al., 2010) 
5.1 Pharmacogenetic markers validation 
Defining clinical guidelines for pharmacogenetic testing has to tackle the following issues: a) 
establishment of clinical end points; b) validation of pharmacogenetic testing in terms of its 
sensitivity, specificity, predictive power, cost-efficiency and time to perform; c) interpretation 
guidelines of the results and their impact on dosing algorithms, population’s stratification, 
clinical trials design, dissemination to clinicians and patients, incorporation into clinical practice 
without major interference to efficiency and cost of health care system. (Loo et al., 2010)  
Pharmacogenetic algorithms should include clinical and genetic factors to guide therapy 
individualization, should be cost-effective and offer supplementary information over 
traditional approaches. However, broader dialogue and additional regulatory guidance are 
needed to reach a consensus regarding: the quantity of pharmacogenetic information in 
drug labels, indications for physicians (informative vs. recommended vs. required 
pharmacogenetic test) and measures to keep this information up to date, relevant sections 
on the labels (which currently ranges from Warnings to Indications to Clinical 
Pharmacology), levels of compelling evidence leading to decision-making translation (i.e., 
type of trial design, sample size, replication, reproducibility, consistency, effect size and 
other predictor variables). (Surh et al., 2010) 
Regulatory recommendations for pharmacogenetic markers concern to: identification of 
responders and nonresponders; reduction of drug toxicity by minimizing or eliminating 
ADR; and optimization of the safety and effectiveness of drugs through personalized dosing 
strategies. This will enhance drug response predictability and safety in preclinical, clinical 
and postmarket trials. The biomarkers could be classified by their purpose in: improving 
drug safety, improving drug efficacy and confirming disease status. The FDA has three 
types of amendments for pharmacogenetic biomarkers, depending on the available evidence 
and the ability to implement the identified biomarker in clinical practice. These are as 
follows: information on the biomarker, which is strictly for informational purposes and does 
not require any action; recommended testing for the biomarker on the label; and mandated 
testing for the biomarker before drug use. (Squassina et al., 2010; Surh et al., 2010; Burns et 
al., 2010) Pharmacogenetic tests validated in clinical studies and recommended in the drug 
labels are detailed in table 1. 
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Drug 
Indication 
Pharmacogenetic 
biomarker 
Comments 
Mandatory, required predictive pharmacogenetic tests in drug label 
Trastuzumab 
HERCEPTIN® 
Metastatic BC 
HER2/neu 
over-expression 
Improve drug efficacy: clinical benefit is limited to the 
responsive patients, whose tumors overexpress the drug-target 
HER2/neu (IHC or FISH assay) 
Lapatinib  
TYKERB® 
Metastatic BC 
HER2/neu 
over-expression 
Improve drug efficacy: clinical benefit limited to tumors 
overexpressing HER2/neu (IHC or FISH assay) 
Cetuximab 
ERBITUX® 
Metastatic CRC 
EGFR expression 
Improve drug efficacy: clinical benefit limited to patients with 
EGFR-positiv tumors (IHC  assay) 
Dasatinib  
SPRYCEL®; 
Imatinib 
 GLEEVEC® 
ALL (adults)  
Philadelphia 
chromosome  
positive 
Disease confirmation and patients’ selection: BCR-ABL 
translocation (Philadelphia chromosome-positiv) 
Maraviroc 
SELZENTRY® 
HIV (adults) 
CCR-5  
C-Cmotif receptor 
Disease confirmation: infection with CCR-5-tropic HIV-1 and 
resistance to other antiretrovirals 
Recommended predictive pharmacogenetic tests in drug label 
Abacavir  
Ziagen® 
HIV infection 
HLA-B*5701 allele  
Improve drug safety: avoid hypersensitivity reactions to 
homozygous or heterozygous HLA-B*5701 genotypes. 
Screening is also recommended in reinitiation of drug in 
populations with previous tolerance of abacavir and unknown 
HLA-B*5701 status.  
Azathioprine, 
IMURAN®;  
 6-MP 
PURINETHOL® 
ALL, 
inflammatory bowel 
disease 
TPMT  
Improve drug safety: avoid myelotoxicity in patients with 
phenotype or genotype of TPMT deficiency or lower activity. 
Subjects homozygous for TPMT∗3A are at high risk for life-
threatening myelosuppression when treated with standard 
doses of thiopurines: individualized doses are one tenth to one 
fifteenth the standard dose, in parallel with careful monitoring 
to avoid myelotoxicity. Patients with intermediate TPMT levels 
can safely receive thiopurines at lower doses (30–50% of the 
standard dose) and safe dose escalation under close 
monitoring. 
Irinotecan 
CAMPTOSAR® 
CRC 
UGT1A1 
First FDA approved pharmacogenetic test “Third Wave 
Technologies, Invader assay” (2005), with dose optimization 
guidelines dependent on UGT1A1 genotype: avoid severe 
(grade III/IV) neutropenia and diarrhoea for those who are at 
high risk, i.e.  homozygous (and possibly heterozygous) for 
UGT1A1*28 and UGT1A1*1 alleles. 
Warfarin 
COUMADIN® 
Thrombo-embolism 
CYP2C9 and 
VKORC1 
(-1639G>A) 
Improve drug efficacy and safety: avoid increased risk of 
bleeding to patients homozygous or heterozygous for 
CYP2C9*2 or CYP2C9*3 alleles by prescribing differentiated 
doses (as compared with those for CYP2C9*1 homozygous). 
Pharmacogenetic test: “Nanosphere Verigene Warfarin 
Metabolism Nucleic Acid Test; therapeutic algorithm based on 
genotype and clinical factors 
(http://www.WarfarinDosing.org.) 
Clopidogrel 
(prodrug) 
PLAVIX® 
Thrombo-embolism 
CYP2C19 
Improve efficacy and safety: doses adjustment for  ultrarapid 
metabolizers who are carriers of CYP2C19*17/*17 genotype and 
for poor metabolizers due to CYP2C19*2 allele presence. 
Carbamazepine 
TEGRETOL® 
Epilepsy 
HLA-B*1502 
allele 
Improve drug safety: avoid serious dermatologic reactions 
(Stevens–Johnson syndrome and/or toxic epidermal 
necrolysis). 
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Drug 
Indication 
Pharmacogenetic 
biomarker 
Comments 
Rasburicase 
ELITEK® 
Hyperuricemia 
G6PD 
Improve drug safety: pre-therapy screening to avoid  severe 
hemolytic reactions associated with G6PD deficiency. 
Clozapine 
CLOZARIL® 
Schizophrenia 
HLA-DQB1 
Improved safety: pharmacogenetic testing, in parallel with 
WBC monitoring, avoid prescription to patients with high 
agranulocytosis risk.  
Test „PGxPredict: Clozapine”  
Tretinoin VESANOID® 
APL 
PML/RAR Improve drug efficacy and safety. 
Disease confirmation by t(15;17) cytogenetic marker  
Valproic acid 
DEPAKENE® 
Seizures 
UCD deficiency 
Confirm disease: consider evaluation of UCD before therapy 
with valproate  
Only informational pharmacogenetic tests in drug label 
Panitumumab 
VECTIBIX® 
Cetuximab 
ERBITUX® 
mCRC 
K-RAS 
Improve efficacy: clinical benefit limited to patients with non-
mutated K-RAS.  
Imatinib  
GLEEVEC® 
GIST 
C-KIT  
Improve drug efficacy: clinical benefit in patients carriers of the 
activating C-KIT mutation 
Busulfan 
MYLERAN® 
CML 
Philadelphia 
chromosome  
Improve drug efficacy: responders are positives for 
Philadelphia chromosome (BCR-ABL) 
Capecitabine  
XELODA® 
CRC 
DPD deficiency 
Improve drug safety: decreased DPD and increased level of 5-
fluorouracil is associated with severe toxicity (e.g., stomatitis, 
diarrhoea, neutropenia and neurotoxicity). 
Primaquine 
Malaria 
G6PD 
deficiency 
Improve drug safety: avoid acute intravascular hemolytic 
reactions. 
Isoniazid, 
Pyrazinamide 
TB 
NAT 
Improve drug safety: dose adjustements based on NAT-
metabolic status, for slow acetylators and fast acetylators to 
avoid severe adverse reaction of peripheral neuropathy, or lack 
of efficacy, respectively. 
Erlotinib  
TARCEVA® 
NSCLC 
EGFR 
mutations 
Confirm disease (at least 10% of the cells are EGFR-positive) 
and response to EGFR tyrosine kinase inhibitors 
Lenalidomide 
REVLIMID® 
Myelodysplasic 
syndromes 
Deletion of 
chromosome 5q 
(del[5q]) 
Confirm disease: indicated to treat those with transfusion 
dependent anemia caused by low- or intermediate-risk of 
myelodysplasic syndromes associated with 5q(del[5q]) 
IHC: immunohistochemistry; FISH: Flourescence In Situ Hybridization; BC: breast cancer; CRC: 
colorectal cancer; EGFR: epidermal growth factor receptor; G6PD: glucose-6-phosphate dehydrogenase; 
ALL: acute lymphoblastic leukemia; 6-MP: 6-mercaptopurine; TPMT: thiopurin-S-methyltransferase; 
UGT: UDP glucuronyltransferase; CYP: cytochrome P450; VKORC1: vitamin K epoxide-reductase 
receptor complex 1; HLA: human leukocytes antigens; APL: acute promyelocytic leukemia; PML: 
progressive multifocal leukoencephalopathy; GIST: gastrointestinal stromal tumor; CML: chronic 
myelogenous leukemia; DPD: dihydropyrimidine dehydrogenase; NAT: N-acetyltransferase; UCD: 
urea cycle disorder; WBC: white blood cells; NSCLC: non-small-cell lung cancer.  
Data taken from: Burns et al., 2010; Squassina et al., 2010; Loo et al., 2010; Spraggs et al., 2009; Sagreiya 
et al., 2010; Seip et al., 2010; Pare et al., 2010; Holmes et al., 2010; McDonald et al., 2009; Shuldiner et al., 
2009; Mega et al., 2009. 
Table 1. Predictive pharmacogenetic tests integrated into drug labels  
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5.2 Clinical trials with genotype-guided design 
Pharmacogenetic cohort studies within randomized controlled clinical trials (RCT) may 
provide final evidence concerning the impact of specific genetic polymorphisms on the 
outcome of drug therapy. Patients are randomly assigned to groups receiving either the 
substance under investigation or the comparison (control) therapy. If pharmacogenetic 
genotypes are analyzed in all the participants in such studies, genotypes that differentially 
predict the response to the administered treatments may be identified. (Stingl & 
Brockmöller, 2011) 
Adequate design and well-controlled clinical investigations with randomization elements 
are defined in the Code of Federal Regulations (CFR) (21CFR 314.126) and they provide the 
FDA with a legal framework for establishing evidentiary standards for approval of a new 
molecular entity, that is, they attest to a drug’s efficacy and safety when used under label 
conditions. In a pharmacogenetic context, RCTs can determine whether a genetic test, on 
average, is beneficial, harmful, or of no clinical value at the population level. When 
comparing the results of RCTs, there is a potential to find conflicting results due to 
differences in the null hypothesis, estimated effect size and study power, patient inclusion 
and exclusion criteria, clinical end points, and methods of data analysis. RCTs also have the 
potential to underestimate clinical events, for example, adverse reactions, when compared 
to ‘‘real-life’’ clinical events. (Lesko, 2007) 
Although randomized controlled trials (RCT) are considered the gold standard for 
demonstrating the efficacy of therapeutic interventions, their application for the validation 
of many biomarkers, especially for multiple SNPs markers derived from GWAS, is limited 
by large sample sizes, time and financial restraints. Although pharmacogenetic studies as 
part of RCT allow to distinguish between prognostic markers and “true” predictive 
pharmacogenetic markers, there might be situations when RCT are unethical to conduct 
such as: the prescription of azathioprine or 6-mercaptopurine to homozygous carriers of 
thiopurine methyltransferase deficiency and the prescription of warfarin to combined 
carriers of low CYP2C9 activity and low vitamin K epoxide reductase complex subunit 1 
VKORC1 activity. (Lesko, 2007) 
Alternatively, carefully designed retrospective and prospective case-control and cohort 
studies based on large, robust databases and conducted with appropriate power and 
corrections, will facilitate the discovery and replication of genotype-phenotype associations. 
Thus, prospective collection and banking of samples with appropriate consent, combined 
with retrospective DNA testing, is a necessity for exploration and potential validation of 
pharmacogenetic biomarkers. (Burns et al., 2010; Frueh, 2009; Stingl & Brockmöller, 2011) 
The case–control study design is the most frequently applied type of observational 
retrospective study in pharmacogenetics and genotype-related disease susceptibility 
research. The frequencies of genotypes in persons identified as having specific adverse drug 
events or poor therapy outcomes (“cases”) are compared with those of concurrently 
sampled controls who have had comparable drug exposure but who do not present the 
particular outcome. The advantages of case–control studies are: moderate resources, 
sufficiently high statistical power, performance in the natural settings of populations, 
focused on one type of well documented drug exposure. However, case–control studies are 
particularly prone to systematic error, also called “bias” and usually they have a supportive 
role requiring data replication in differently designed studies. (Stingl & Brockmöller, 2011) 
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The case–control Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation 
(SHAPE) showed that 100% of both white and black patch test-positive patients carried 
HLA-B*5701, suggesting a 100% negative predictive value of HLA-B*5701 for abacavir HSR, 
generalizable across race. (Saag, 2010 as cited in Phillips et al., 2011) 
A pharmacogenetic cohort study involves no controls and the group of patients receiving 
one type of therapeutic intervention is defined at the initiation of therapy and followed over 
the course of the study. This study design reflects true medical reality, is relatively easy to 
perform, and produced less biased results. In the time-series modified design, each patient 
serves as his or her own control because the drug treatment period is interrupted by a 
placebo period, thus a more precise differentiation between the drug effect and the effects of 
other factors may be obtained. The major drawbacks of cohort studies are: low statistical 
power requiring larger samples; a significant risk of confounding if there is heterogeneity in 
drug treatments, disease stages, and disease severity within the study sample; impossibility 
to differentiate between predictive and prognostic genotypes; insufficiency to serve as the 
only basis of therapy recommendations incorporating pharmacogenetics. (Lin & Chen, 2008 
as cited in Stingl & Brockmöller, 2011) 
Prospective interventional pharmacogenetic trials are based on the sequential pre-post or 
before-after design and patients receive drug therapies first before genotyping and then 
again after genotyping; sometimes it is also included a concurrently studied comparison 
group (parallel-controlled pharmacogenetic study) that implies randomized allocation to 
either the “therapy-guided by pharmacogenetic” arm or the “therapy as usual” arm. 
Prospective interventional pharmacogenetic trials allow a comparison between the efficacy 
of a new mode of treatment and that of the usual therapy and the extent to which the 
outcome of drug therapy would improve if it is guided by predictive pharmacogenetic 
testing. Randomized parallel diagnostic trials are more expensive, difficult to blind 
pharmacogenetic testing and might require larger sample sizes than phase III drug trials. 
(Haga et al., 2009 as cited in Stingl & Brockmöller, 2011) 
Prospective on-going clinical trials with genotype-guided design may be illustrated by: a) 
IDANAT2 (“Isoniazid Dose Adjustment According to NAT2 Genotype”), initiated in Europe 
since 2008, aims to comparatively evaluate efficacy and liver toxicity of  isoniazid 
administered in adjusted doses upon slow or fast acetylator status; b) phase II trial in North 
America on therapeutic strategy choice based on the presence of genotype tymidilate 
synthase TYMS TSER*3 “increased-risk” allele to the non-responders to fluoropyrimidines; 
c) phase III trial on rosiglitazone efficacy in Alzheimer’s patients stratified by APOE4 allele 
presence or absence; d) prospective study on Lapatinib (TYKERB) efficacy in metastatic 
breast cancer overexpressing Her2/ErbB2 to identify biomarkers of acquired 
chemoresistance to initial anthracyclins, taxans and trastuzumab therapy. (Spraggs et al., 
2009) 
PREDICT-1 is the first powered, randomized, blinded, prospective trial to evaluate the 
clinical utility of prospective pharmacogenetic screening for HLA-B*5701 to reduce the 
incidence of abacavir hypersensitivity in an abacavir-naïve population of HIV-infected 
subjects. (Hughes et al., 2008)  
GENDEP is the largest prospective study to examine the interaction of a moderate effect size 
between genetic (SLC6A4 variants) and clinical predictors (stressful life event - SLE) on 
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response to antidepressants escitalopram and nortriptyline. The occurrence of antecedent 
SLEs predicted response to escitalopram and these effects were moderated by two 
functional polymorphisms 5-HTTLPR and STin4 in gene SLC6A4 encoding the serotonin 
transporter. (Keers et al., 2011) 
The large, randomized controlled clinical trials COAG and EU-PACT (European 
Pharmacogenetics of Anticoagulant Therapy) will establish the safety and clinical utility of 
genotype-guided dosing in daily practice for the three main coumarin derivatives (warfarin, 
acenocoumarol, phenprocoumone) used in Europe, measuring as primary outcome the 
percentage time in the therapeutic range for international normalized ratio. (van Schie et al., 
2009; Squasina et al., 2010) In the meantime, a new rapid and inexpensive Allele-Specific 
Amplification (ASA)-PCR genotyping assay for vitamin K antagonist pharmacogenetics was 
validated that may reduce the frequency of over- and undertreatment patients, especially 
during drug initiation, and thus will improve patient safety. (Spohn et al., 2011) 
5.3 Pharmacogenetics in drug design and development 
Pharmacogenetics is integrated in all phases of drug discovery and development. A) 
Preclinically, in high-throughput screening of whole genome expression profile in 
interaction with drugs and validation of new “druggable” targets; identification the ADME 
polymorphisms relevant to the investigational substance and evaluate ADME genotyping in 
all subsequent clinical studies; prediction of the risk of allergy and organ toxicities in 
carriers of specific genotypes before first application in humans. B) In phase I, identification 
and validation of pharmacogenetic biomarkers obtained from preclinical data in order to 
stratify patients into genotypic segments of responders vs. non-responders; guide phase II 
trials design; explain the lack of efficacy or adverse drug reactions, in more cost-effective 
manner than later, in separate human pharmacogenetic studies. C) In phase II, guide 
evidenced-based decisions about further development of the investigational substance; 
potential for further drug/genotype test co-development in phase III. D) Phase III, extensive 
biomarker research for clear evidence-based data concerning pharmacogenetics for drug 
labeling (genotype-defined subgroups having particularly high efficacy or high risk for 
ADR); improving risk–benefit ratio in the case of label extension; identification of innovative 
treatment principles and drug targets; enrollment in the phase III-IV clinical trials only of 
the group of patients highly predictable to respond to therapy and excluding those with 
high risk of adverse drug reactions according to genotype. E) Pharmacovigilance in the post-
marketing phase of drugs allows optimization and label changes of approved drugs to 
include pharmacogenetic genotyping in order to exclude patients who carry genotypes 
predicting high risk ADR or no response. F) Reconsideration of potentially valuable drugs 
withdrawn because of adverse drug effects by excluding carriers of risk genotypes and by 
indicating only to genotypes predictive for high efficacy. (Stingl & Brockmöller, 2011) 
Pipeline pharmacogenetics marks the change from the current lag phase towards the log 
phase, thus accelerating the rate of marketed new chemical entities, reducing the attrition 
rate during the expensive late phase clinical development, increasing the benefit to risk ratio 
through early identification of nonresponders or those individuals with high risk of ADRs, 
especially if the critical proof of concept for efficacy is prospectively predicted in the 
protocol for a clinical trial so as to be regarded by regulators as hypothesis testing. 
Pharmacogenetics has determined a paradigm shift within pharmaceutical industry towards 
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a ‘‘mini-blockbuster business model’’, thus recognizing its significant commercial and 
success rate contribution. (Lesko, 2007) Among other pipeline pharmacogenetics’ benefits 
for pharmaceutical companies are: the opportunity to reconsider drugs which were initially 
stopped during development or withdrawn from the market; the ability to avoid investing 
in unfavorable products at earlier stages of development; the higher quality and more 
effective clinical trials design; reduction of research and development costs and periods; 
favorable impact on profit by increasing peak sales correspondent to a higher market share 
much earlier during the commercial life of the drug. For example, Eli Lilly has applied the 
tailored therapy strategy for drugs Xigris and Strattera. (Lechleiter, 2009, as cited in Fackler 
& McGuire, 2009; Roses, 2009) 
Stingl and Brockmöller realize a comparative analysis of a variety of pharmacogenetics-
related study designs integrated in all phases of drug development and clinical practice, 
evaluating  the following issues: type and quality of evidence gained by each category of 
study design, their appropriated timeliness, as well as their pros and cons. The authors 
underline the necessity for new study designs for the clinical application of 
pharmacogenetics knowledge, as well as for mandatory requirements for the comprehensive 
characterization of relevant genetic variation in drug development. Future prospective 
interventional pharmacogenetic-trials in a genotype-preselected or outcomes-preselected 
population might represent one possible strategy to increase power in pharmacogenetic 
research at acceptable cost levels, especially to discover and validate the impact of genetic 
polymorphisms on drug response variability on the difficult-to-treat patients (poor-
responders or severe adverse reactions) and in the elderly, on drug–drug interactions, or 
gene-gene interactions. (Stingl & Brockmöller, 2011) 
Successful application of pipeline pharmacogenetics should meet some basic requirements, 
such as: obtaining the appropriately-documented informed consent;  collection and storage 
of DNA samples for regulatory submission; implementing predictive exploratory 
pharmacogenetics studies on candidate gene and pathway-associated SNPs (rather than 
GWAS) during phase I clinical trials to generate hypothesis for early phase IIA, followed by 
hypothesis testing during phase IIB, in order to increase the statistical significance within a 
relatively smaller, well-defined group of patients. However, standardized methodologies 
should be established regarding: specification of sample source, standardization of 
diagnostic systems and treatments, adequate monitoring, sufficient length of observation, 
inclusion of possible confounding factors. (Roses, 2009; Spraggs et al., 2009) 
The cost of pipeline pharmacogenetics is much lower in comparison with the cost of clinical 
trials and drug attrition. The advantages of large public-private partnerships at all stages of 
drug development in order to accelerate new medicines approval and biomarkers 
qualification and validation for selection of patients for clinical trials, monitoring drug 
effects and safety risk, regulatory guidelines harmonization and implementation, are 
illustrated by Eck and Paul. (Eck & Paul, 2010) 
6. Pharmacogenetics’ perspectives and challenges 
High priority directions in the pharmacogenetic research for maximizing its potential 
benefit for personalized medicine are: 1) Chronic diseases (hypertension, diabetes, asthma, 
epilepsy, multiple sclerosis etc) which imply: high costs for healthcare system and patients, 
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considerable management care costs; polymedication; low clinical outcomes due to 
compromised patients’ quality of life, continuous suffering and low compliance to 
medication. 2) Medications with long adjustment periods of therapeutic doses and currently 
prescribed on “trial-and-error” basis, resulting in reduced compliance rates and increased 
management care costs. 3) Drugs with narrow therapeutic index (mercaptopurine, warfarin) 
that require close monitoring and constant dosage adjustment procedures to maintain 
therapeutic efficacy and minimize adverse reactions. 4) Drugs with severe, life-threatening 
adverse reactions which require high hospitalization costs (abacavir). 5) Very expensive 
medications with high clinical efficacy in some segments of population and for which a 
predictive diagnostic test might be developed (herceptin). (Grossman & Goldstein, 2009) 
Pharmacogenetic testing is already implemented in some clinical areas, such as in 
cardiovascular diseases or in cancer, for selecting and/or dosing a specific medication, while 
in other fields, such as in psychiatry, the pharmacogenetic approach has been mostly used 
for the identification, validation and development of new meaningful biomarkers. 
(Squassina et al., 2010) 
Of particular interest is pediatric pharmacogenetics that should consider both variation  
in gene expression and developmental context in which the genes of interest are functionally 
active (ontogeny). Apart from the application of pharmacogenetic testing to children  
for thiopurine-induced myelotoxicity, no other genotype-drug response associations 
validated in adults have been conclusively validated and no diagnostic or pharmacogenetic 
dosing algorithms have been so far translated in pediatric patients. (Ross CJ et al., 2011; 
Becker & Leeder, 2010) In order to achieve this gap, the Canadian Pharmacogenomics 
Network for Drug Safety (CPNDS) has implemented an active and targeted adverse drug 
reaction surveillance in pediatric patients with the aim of functional validation of identified 
gene markers, such as: warfarin-induced bleeding and thrombosis, vincristine-induced 
peripheral neuropathy, glucocorticoid-induced osteotoxicity, methotrexate-induced 
mucositis or leukoencephalopathy or nausea and vomiting, anthracycline cardiotoxicity, 
cisplatine-induced ototoxicity, neurotoxicity and nephrotoxicity. The final objective is to 
ensure generalizability of clinically significant findings and translation into a 
pharmacogenetic test of each predictive biomarker evaluated in prospective clinical trials 
(such as those dedicated to cisplatin ototoxicity and codeine-induced mortality in breastfed 
infants by mothers who are CYP2D6 ultrarapid metabolizers and UGT2B7*2 homozygous 
carriers), as well as to provide a cost–benefit analysis for validated predictive biomarker. 
(Loo et al., 2010) 
6.1 Translational challenges  
Successful integration of pharmacogenetics into future clinical practice and personalized 
medicine should overcome further translation barriers related to: a) global problems of 
scarcity of data demonstrating pharmacogenetic testing’s clinical validity and utility; b) 
standardized and powerful statistical correlations between genotype and drug-response 
phenotype across different populations; c) education of health professionals and public; d) 
pharmacoeconomics issues; e) bioethical and social aspects; f) more favorable regulatory 
policy for clinical uptake of pharmacogenetics via sustaining large-scale industry-academia 
collaborations; g) the adoption of harmonized and standardized guidelines for biorepository 
and data sharing across multi-national networks; h) lack of incentives for the private sector 
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to invest in the development and licensing of pharmacogenetics diagnostic tests for 
improving the safety and efficacy of out-of-patent drugs. (Spraggs et al., 2009; Gurwitz et al., 
2009) 
Scientific community and International Society of Pharmacogenomics Education Forum 
have called for the enhanced implementation of pharmacogenomics and personalized 
medicine into core medical teaching curricula and practice, in order to fill in the gap 
between intensive research on validated pharmacogenetic testing and its appropriate, 
effective clinical integration and interpretation in routine individualized therapy. (Squassina 
et al., 2010) For instance, Pharmacogenomics Education Program (PharmGenEd™) is an 
educational platform for dissemination of evidence-based clinically relevant 
pharmacogenomics, fostering educational and scientific collaboration among educators, 
researchers and clinicians (http://pharmacogenomics.ucsd.edu). PharmGenEd also 
participates along with Pharmacogenomics Knowledge Base (PharmGKB) and National 
Institute of Health Pharmacogenomic Research Network (NIH PGRN), in the Clinical 
Pharmacogenetics Implementation Consortium (CPIC) to create a curated resource for 
storing, annotating and updating specific data relevant for clinical implementation of 
pharmacogenetic testing. (Kuo et al., 2011) 
The adoption of the pharmacogenetics tests for personalized medicine depends on clinical- 
and cost-effectiveness analyses on which the reimbursement for their routine use will be 
based. (Liewei et al., 2011) In the context of pharmacoeconomic models, pharmacogenetic 
testing might be regarded more cost-effective than cost-saving, or at least cost-effective for 
particular combinations of treatment, genetic polymorphisms and disease, depending 
greatly on the differences among healthcare systems and reimbursement policies.  
(Squassina et al., 2010; Trent, 2010) 
Appropriate protection for privacy and confidentiality of databases with large amount of 
genotypic, phenotypic and demographic data regarding individuals is crucial in order to 
avoid the possible risk of psychosocial harm, genetic and social discrimination, privacy and 
possible implications for employment and access to life and health insurance. (Squassina et 
al., 2010) Moreover, pharmaceutical companies could voluntarily ignore, for economic 
reasons, patients with rare or complex genetic conditions or those who are not responding 
to any known treatment, leading to consequent deprivation of effective treatments. These 
concerns are attenuated by USA specific regulations, such as the Genetic Information 
Nondiscrimination Act (GINA), the Health Insurance Portability and Accountability Act 
Privacy Rule, and the Genomics and Personalized Medicine Act (GPMA), as well as by 
founded nonprofit organizations of major key stakeholders (pharmaceutical companies, 
healthcare providers and payers, patient advocacy groups, industry policy organizations, 
academic institutions and government agencies), like the Personalized Medicine Coalition 
and Pharmacogenetics for Every Nation Initiative (PGENI). (Squassina et al., 2010)  
Taking into account the ethical, legal and social issues of pharmacogenetics research, as well 
as the multi-disciplinary opinions of the key stakeholders, Howard and colleagues have 
identified six outstanding ethical issues raised by the informed consent process in 
pharmacogenetics research and proposed valuable recommendations  for the development 
of future practical pharmacogenetics consent guidelines, such as: 1) scope of consent; 2) 
consent to pharmacogenetics ‘add-on’ studies; (3) confidentiality, privacy protection and 
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coding of personal information in long-term databases, especially in those controlled by 
private pharmaceutical companies; (4) intellectual property and commercialization policy of 
pharmacogenetics research projects with financial benefit-sharing plan; (5) disclosure of the 
possibility of deposition and sharing in public repository of the samples and data, at the 
onset of the pharmacogenetics study; (6) potential risks stemming from population-based 
research so as to avoid overgeneralizations and  undermining the moral, cultural and 
religious standards. (Howard et al., 2011) 
6.2 Pharmacogenetics’ perspectives by next generation sequencing 
GWAS are particularly useful to determine the most significant SNPs associated with a 
phenotype amongst a high-density set of polymorphisms, in cases where there are large 
cohorts to evaluate, clinical end points are simple to define without variability, and the 
genetic factors associated with the end points are highly penetrant. However, GWAS are 
discovery- rather than hypothesis-driven, result in weak statistical power and false 
positives, need large sample size, cost and computing power requirements. Therefore, 
GWAS imply a two-stage design where discoveries made using a high-density SNP array 
are then validated using a hypothesis design on replicative populations. (Sissung et al., 
2010) Nonetheless, for ADR with a significant genetic component that confers a large effect 
(carbamazepine-induced Stevens–Johnson syndrome, abacavir-induced hypersensitivity, 
statin-induced myopathy and gefitinib-induced diarrhoea), associations can be identified 
with a relatively small number of samples (10–100 cases). (Loo et al., 2010; Davis & Johnson, 
2011) 
Rare variants in complex mixtures of DNA might be quantitatively measured by mass 
spectrometry-based genotyping. Fluidigm‘s microfluidic device (“lab-on-chip”), able to mix 
96 samples and 96 primer sets in nano-scale assay chambers that support over 9000 parallel 
qRT-PCR reactions, could be also used for genotyping and targeted sequence capture; thus 
filling the gap between biomarker evaluation of a few candidate genes and the hundreds of 
markers GWAS-discovered. (Gibson, 2011) 
The development of next-generation sequencing (NGS) or massively parallel sequencing, as 
well as nanopore sequencing technologies, through whole-genome, whole-exome and 
whole-transcriptome analysis, allows fast, inexpensive, reliable production of large volumes 
of DNA or RNA sequence data. (Metzker, 2011; Tucker et al., 2009) NGS comprises a 
number of methods that are grouped broadly as template preparation, sequencing and 
imaging, genome alignment and assembly, and data analysis. The unique combination of 
specific protocols distinguishes one technology from another and determines the type of 
data produced from commercial platforms such as: Roche/454, Illumina/Solexa, Life/APG 
and Helicos BioSciences, the Polonator instrument and the Pacific Biosciences. The NGS 
technologies, their broad applications and guidelines for platform selection to address 
biological questions of interest are reviewed by Metzker (Metzker, 2011). Having aligned the 
digested fragments of individuals’ targeted regions of genome to a reference genome, ‘SNP 
calling’ identifies variable sites, whereas ‘genotype calling’ determines the genotype for each 
individual at each site, thus revealing principal types of genome alterations (like nucleotide 
substitutions, small insertions and deletions, copy number alterations, chromosomal 
rearrangements). (Rasmus et al., 2011) Computational, biological and clinical analyses of the 
resulting genome data will assess reproducibility and statistical significance; links to 
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pathways and the functional relevance of mutated genes to disease; and the relationships of 
genome alterations with cancer prognosis and response to therapy, respectively. (Meyerson 
et al., 2010)  
Over a relatively short time frame, DNA sequencing has become cheaper and faster  
(US$ 1,000 price tag for a whole human genome sequence now seems feasible) and even 
more with the foreseeable third-generation DNA sequencers utilizing single molecules and 
avoiding initial cloning or amplification steps. (Trent, 2010; Pushkarev et al., 2009)  
In addition to NGS rapid technological developments, the promotion of alternative 
strategies for delivery of healthcare through nontraditional pathology laboratories, such as 
direct-to-consumer (DTC) DNA tests and point-of-care DNA testing, will expand the 
integration of pharmacogenetics into clinical practice by assisting health practitioner to 
make on-the-spot decisions about the individualisation of drug and dose directly at the 
bedside in the intensive care unit or consulting room. (Trent, 2010) 
6.3 New players in pharmacogenetics: Alternative splicing, miRNAs and structural 
RNA polymorphisms 
In addition to polymorphisms in protein-coding genes (nonsynonymous SNPs) associated to 
complex diseases, alternative splicing in protein-coding genes and variations in microRNAs 
and other noncoding RNAs have emerged as new players in pharmacogenetics and they 
should be considered in an integrative approach in deciphering the genotype-induced inter-
individual variability of drugs’ tolerance, efficacy and metabolism.  
Alternative splicing of pre-mRNAs was proposed 30 years ago by the Nobel Prize winner 
Walter Gilbert as a way of generating different mRNAs from a single gene and it is regarded 
as one of the most elegant and important mechanisms for proteome diversity generation. 
Alternative splicing in protein-coding genes can affect the biological activity of proteins, 
having major consequences on drug metabolism and drug response phenotype. Generation 
of wrong alternative splicing variants is a common feature of complex diseases and also an 
important player in drug resistance and ADME. For example, alternative splicing variants in 
the BCR–ABL fused gene were correlated with Imatinib mesylate resistance in chronic 
myelogenous leukemia patients (Gruber et al., 2006, as cited in Passetti et al., 2009); whereas 
splicing isoforms of nuclear pregnane and constitutive androstane receptors can affect the 
pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients. 
(Horr et al., 2008, as cited in Passetti et al., 2009) The functional relevance of alternative 
splicing of pre-mRNAs and generated splice variants in the context of whole genome 
studies instead of a single gene would reveal how they will affect cellular networks and 
pathways. (Passetti et al., 2009) 
The noncoding RNAs (ncRNAs) are a large group of transcripts lacking protein-coding 
potential, having variable size range from approx. 18 to 25 nucleotides for the families of 
microRNAs (miRNAs) and small interfering RNAs (siRNAs), approx. 20 to 300 nucleotides 
for small RNAs commonly found as transcriptional and translational regulators, or up to 
and beyond 10 000 nucleotides in length for RNAs involved in various other processes. 
(Costa FF, 2008, as cited in Passetti et al., 2009) miRNAs are noncoding RNAs that can 
regulate gene expression by Watson–Crick base pairing to target several mRNAs in a gene 
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regulatory network. The binding of miRNAs to their target mRNAs is critical for regulating 
mRNA levels and therefore protein expression. miRNAs are master regulators of important 
gene and transcriptome networks in eukaryotic cells, they can block mRNA translation and 
affect both the expression of at least 30% of all protein-coding genes by targeting their 3'-
UTR sequences and long ncRNAs. A growing number of reports have been showing the 
associations of deregulated expression of miRNAs in complex diseases (cancer, obesity, 
diabetes, schizophrenia) by altering the regulation of expression of many important genes. 
One miRNA can downregulate multiple target proteins by interacting with different target 
mRNAs ('one hit multiple targets' concept), thus pointing out the particular therapeutic 
relevance of miRNAs as an attractive drug target. (Wurdinger & Costa, 2007, as cited in 
Passetti et al., 2009) Moreover, polymorphisms in miRNAs represent a newly identified type 
of genetic variability that can influence the risk of diseases and also variability in 
pharmacokinetics and pharmacodynamics of drugs. For instance, polymorphisms in 
miRNA target sites of protein-coding genes are associated to cancer, hypertension, asthma, 
cardiovascular disease, and polymorphisms in microRNAs are associated with 
schizophrenia, Parkinson. (Passetti et al., 2009) In addition, long ncRNAs, increasingly seen 
as functional genes, have been involved in disease progression, such as: ZNFX1-NA1 in 
breast cancer, SPRY4-IN in melanoma; NEAT1 long ncRNA in Alzheimer. (Gibson, 2011) 
Alternative splicing might affect microRNA regulation and subsequently microRNAs are 
able to regulate hundreds of effector genes in a multilevel regulatory mechanism that allow 
individual miRNAs to profoundly affect the gene expression program in the cells. Both 
microRNA regulation and alternative splicing will induce changes in proteome diversity 
that can affect the way drugs are metabolized by patients, and this will have major 
implications for both drug design and personalized medicine in the future. Furthermore, 
genetic variations in the sequence of miRNAs, target sites of miRNAs and alternative 
splicing will affect gene regulatory networks and pathways responsible for drug metabolism 
and resistance, thus emerging as a new paradigm clearly redefining the pharmacogenomics 
field and personalized medicine. (Passetti et al., 2009) 
Structural RNA SNPs (srSNPs) designate genetic polymorphisms in the transcribed regions 
of genes that affect RNA functions and represent ~49% (synonymous SNPs, 2%; those in 5′- 
and 3′-untranslated regions, 2%; intronic, 45%) from disease-associated SNPs derived from 
GWAS, whereas nonsynonymous (coding  cSNPs) account for only ~9% and regulatory 
SNPs (rSNPs; SNPs in intergenic regions that alter transcription of protein-coding genes) for 
~43%. (Hindorff et al., 2009, as cited in Sadee et al., 2011) Structural RNA SNPs affect RNA 
functions such as splicing, turnover and translation, having tissue-specific effects, while 
regulatory single-nucleotide polymorphisms (rSNPs) affect transcription. (Sadee et al., 2011) 
Recent GWAS and next-generation sequencing of the transcriptome have opened path for 
large-scale exploration of mRNA expression quantitative trait loci (eQTLs) which are 
commonly categorized as rSNPs affecting transcription and altering mRNA expression 
levels in target tissues. (Sadee, 2009, as cited in Sadee et al., 2011) Furthermore, the 
evaluation of allelic ratios of transcripts would enable the detection of rSNPs and srSNPs, by 
revealing any deviation from unity expected in an autosomal gene - termed “allelic 
expression imbalance” (AEI) – that indicates the presence of cis-regulatory factors and 
represents a more precise relative measure of transcript activity as compared with total 
mRNA levels. (Johnson, 2008, as cited in Sadee et al., 2011) Structural RNA polymorphisms 
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will likely prove essential to fill gaps in the “missing heritability”, substantially contributing 
to discover pharmacogenetic biomarkers of increased predictive power. The clinical 
relevance of rSNPs and srSNPs has greatly contributed the available validated predictive 
genetic variants. For example, there are validated srSNPs and rSNPs in DME (CYP2C19, 
CYP2D6, CYP3A5, UGT1A1, NAT1, ABCB1, ABCC2) associated with variability in the 
bioactivation, pharmacokinetics and clinical outcome of clopidogrel, tamoxifen, statins, 
efavirenz, tacrolimus, paclitaxel, antiretrovirals. Moreover, validated srSNPs and rSNPs in 
genes that encode drug targets (D2 dopamine receptor gene  DRD2) are associated with 
poor response to antipsychotics or with risk for metabolic syndrome (rSNPs in gene TPH2 
encoding tryptophan hydroxylase). (Sadee et al., 2011) 
6.4 Pharmacogenetics’ perspectives by biobanking and electronic health records 
Global surveys conducted by the Industry Pharmacogenomics Working Group (I-PWG) in 
order to determine current industry and institutional review boards/ ethical committee 
(IRB/EC) practices, policies and standards, for prospective biospecimens’ collection and 
storage for pharmacogenomics research, emphasize the significant value of pharmacogenetics 
research and biobanking for personalized medicine, as well as the necessity for harmonization 
and standardization across the industry and the key stakeholders in regulations concerning: 
sample acquisition and data privacy protection, pharmacogenetics-related language in 
informed consent, outsourcing of DNA sample storage, “clinical relevance” of the genetic 
information to be returned to the patients, benefits and foreseeable risks. (Franc et al., 2011a, 
2011b; Warner et al., 2011; Ricci et al., 2011) 
The creation of a biorepository that are closely link with electronic medical records (EMR) 
may be an economically efficient approach to genomic medicine and especially to GWAS 
that require DNA sample from large populations with robust phenotypic data. The 
Geisinger MyCode Biorepository is perhaps the first large-scale biobanking project around 
EMR. In addition, a data warehouse project – the Clinical Decision Information System – 
initiated in 2006 aims to assembly in a single point of reference 40 different data sources 
regarding patients’ clinical phenotype, biobanks, clinical trials databases, as well as 
financial, administrative, operational and patient survey databases. Such data warehouses 
allow optimizing performance, maintaining control and privacy aspects, reliability, 
robustness and fast-response. (Gerhard et al., 2009) 
Large multi-national consortia have been already established, such as NIH-funded PGRN, 
and NIH-funded Electronic Medical Records and Genomics Network (eMERGE), which are 
catalogued in Pharmacogenomics Knowledge Base. (McCarty & Wilke, 2010) 
The convergence of the rapidly expanding biomedical informatics, high-throughput 
genotyping, DNA biobanks and EMR across large health-care networks, plays a pivotal role 
in pharmacogenomics’ translation to the bedside. Through real-time monitoring of multiple 
de-identified EMR databases integrated in sophisticated cross-institutional networks (e.g., 
the PGRN, the eMERGE network, and the HMO Research Network, Harvard 
University/Partners Healthcare system i2b2, the Vanderbilt BioVu), highly accurate 
quantifying disease phenotypes  and treatment outcomes could be efficiently extracted by 
the application of natural language processing (NLP), semantic interoperability, data 
normalization strategies and novel bioinformatics platforms. The following translational 
www.intechopen.com
Pharmacogenetics:  
Matching the Right Foundation at Personalized Medicine in the Right Genomic Era 
 
29 
mechanisms are envisaged: (i) retrospective assessment of previously known findings in a 
clinical practice-setting; (ii) discovery of new associations in huge observational cohorts; (iii) 
prospective application in a setting capable of providing real-time decision support; iv) 
enhance pharmacovigilance, especially during the postmarketing phase; vi) validation of 
previous conventional cohort-driven GWAS, in a cost-effective, earlier and more accurately 
manner. (Wilke et al., 2011; Kohane, 2011) In addition, electronic health records-driven 
genomic research (EDGR) will provide a rich set of comprehensive clinical phenotypes, in 
close to real time, at a low cost and a high degree of timeliness, matched to the 
corresponding DNA samples from biorepositories. The cost-efficiency advantage of EDGR 
comes from maximizing the research utility of that clinical-care investment such that it is 
only a fraction of a de novo research cohort pipeline. Other advantages of EDGR include: 
ability to assess in-depth the clinical significance of genomic associations; great 
representation of a clinical population; data on environmental exposures; broad and 
accurate reflection of clinical phenotypes and controls; identification of confounders. 
(Kohane, 2011) In the future, as standardization across national biobanks-linked EMR, 
consent procedures and ownership of the derived intellectual property will be adopted, 
genetic data will be recorded preemptively into each patient’s EMR, and robust biomedical 
informatics platforms will interrogate this information during the process of clinical 
decision making, providing efficient real-time decision support at the point of care. (Wilke et 
al., 2011; Kohane, 2011)  
Development of simple, up-to-date, easily accessible, reliable clinical algorithms and 
guidelines must guide physicians in the interpretation of genetic data, decision making 
about diagnostic testing and follow-up clinical care. These point-of-care tools will be 
embedded in electronic health records system and it will be crucial to accelerate the 
individualized medicine. (Fackler & McGuire, 2009; Liewei et al., 2011) 
In addition, the implementation of robust health information technology able to 
electronically manage all different types of -omics biomarker data and phenotypic 
characterization of research study participants, might be illustrated by software platforms 
like: Hewlett-Packard’s Gateway for Integrated Genomics - Proteomics Applications and 
Data (GIGPAD) or Microsoft’s Amalga. (Fackler & McGuire, 2009) 
The National Institute of Health’s Pharmacogenomics Research Network (PGRN) is a 
collaborative partnership of research groups funded “to lead discovery and advance 
translation in genomics in order to enable safer and more effective drug therapies”, with the 
ultimate goal to predict and personalize medicine in routine clinical practice. (Long & Berg, 
2011) PGRN’s accomplishments and future projects to provide peer-reviewed, updated, 
evidence-based, freely accessible guidelines for gene/drug pairs, so as to facilitate the 
translation and interpretation of preemptive pharmacogenomic tests for the most relevant 
pharmacogenes from laboratory, through electronic medical records system, into decision-
making prescription recommendations, have been extensively discussed. (Long & Berg, 
2011; Roden & Tyndale, 2011; Relling & Klein, 2011) 
6.5 Further perspectives in pharmacogenomics 
Further perspectives for pharmacogenomics to emerge as an important piece in the puzzle 
of personalized medicine will concern: a) the integration of pharmacogenomics with 
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additional, non-drug-related patient characteristics, individual disease factors, and 
environmental aspects (Kroemer, 2010); b) tissue-specific epigenetic changes, microRNAs or 
“junk DNA” (Trent, 2010); c) discovery of useful pharmacogenetic markers in the 
mitochondrial DNA (mtDNA) within transmitochondrial cell lines or cybrids in order to 
optimize antibiotherapy (Squassina et al., 2010); d) biomarkers validation for drug therapy 
in organ transplantation and for complex diseases characterized by a great phenotypic and 
genetic variability; e) coordinated implementation into certified laboratories of the 
pharmacogenes’ next-generation-sequencing, according to GCP guidelines; f) the adaptation 
of the regulatory and reimbursement environment. (Fackler & McGuire, 2009) 
Moreover, nanotechnology is projected to play a critical role in personalized medicine, 
greatly dependent on the evolutionary development of a systems biology approach to 
clinical medicine based upon “-omic” technology analysis and integration. In a 
comprehensive review, Sakamoto and colleagues analyse: the current state of nano-based 
products over a vast array of clinical indications and patient specificity;  rational design of 
nanotechnologies for individualized therapy; nano-based injectable therapeutics, 
implantable drug-delivery devices; nanotechnology and tissue engineering; nanowires and 
cantilevers arrays that are used to detect minute amount of protein biomarkers. (Sakamoto 
et al., 2010) 
7. Conclusions 
Pharmacogenomics is the interface between genomic medicine and systems pharmacology 
and its translation from bench into clinical practice is broadening the perspective of 
personalized medicine so as in the near future we might rely on a “DNA 
chip”/“pharmacogenomic card” specific to each patient and on each genotype preemptively 
recorded in EMR, in order to individualize both the diagnostic procedures and the safest 
and most efficient medications prior to treatment initiation. Although it is still regarded as 
an elusive dream due to limited marketed drug–test companion products and actually 
implemented clinical practices, pharmacogenomics translation into personalized medicine 
has become a more imminent reality. Advances in next-generation sequencing technology to 
uncover the contribution of “missing heritability” to biomarker-guided therapeutic 
individualization, the convergence of biorepositories- and electronic health records-
pharmacogenomics research, the encouraging initiatives for policy and guidelines 
harmonization, as well as extensive collaborations across large pharmacogenomic  
networks, will hopefully overcome the current challenges ahead on the road to personalized 
medicine and will play a pivotal role in pharmacogenomics’ translation  to the bedside. 
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